DiCE Molecules Revenue and Competitors

Location

$187.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DiCE Molecules's estimated annual revenue is currently $17.2M per year.(i)
  • DiCE Molecules's estimated revenue per employee is $155,000
  • DiCE Molecules's total funding is $187.4M.

Employee Data

  • DiCE Molecules has 111 Employees.(i)
  • DiCE Molecules grew their employee count by 25% last year.

DiCE Molecules's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M26-16%N/AN/A
Add Company

What Is DiCE Molecules?

DiCE Molecules is a privately-held company focused on the development of small molecule compounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. Utilizing its unique approach, DiCE can amplify the strongest potential drug candidates and, by combining massive diversity with amplification and selection, substantially increase the probability of success.

keywords:N/A

$187.4M

Total Funding

111

Number of Employees

$17.2M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DiCE Molecules News

2022-03-30 - Neuron23 Closes $100M Series C Financing

... life sciences and venture capital companies, including Dice Molecules, Adverum Biotechnologies, One Ventures, and Blade Therapeutics.

2021-08-24 - DiCE Molecules Raises $60M in Series C-1 Financing

DiCE Molecules, a San Francisco, CA-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, completed its $60m Series C-1 financing. The round was led by RA Capital Ma ...

2021-08-24 - DiCE Molecules : Announces $60 Million Series C-1 Financing

DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, today announced the completion of its $60 million Series C-1 financing. The financing was led by RA ...

2021-01-11 - Dice Molecules secures $80M

RA Capital Management has led an $80 million Series C for Dice Molecules, a biopharmaceutical company that focuses on immunology. The company plans to use the funding in part to advance clinical trials of one of its oral medicines. Select Additional Investors Northpond Ventures, New Leaf Ventu ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.2M111-7%N/A
#2
$19.4M1146%N/A
#3
$30.8M114-7%N/A
#4
$15M1175%N/A
#5
$16.5M118-1%$30M